US 7,361,463 B2
	Muteins of hypoxia inducible factor alpha and methods of use thereof
William G. Kaelin, Jr., Boston, Mass. (US); and Mircea Ivan, Cambridge, Mass. (US)
Assigned to Dana Farber Cancer Institute, Inc., Boston, Mass. (US)
Filed on May 26, 2004, as Appl. No. 10/854,483.
Application 10/854483 is a continuation of application No. 10/101816, filed on Mar. 19, 2002, granted, now 6,849,718.
Claims priority of provisional application 60/345132, filed on Dec. 20, 2001.
Claims priority of provisional application 60/342598, filed on Dec. 20, 2001.
Claims priority of provisional application 60/345131, filed on Dec. 20, 2001.
Claims priority of provisional application 60/345200, filed on Nov. 09, 2001.
Claims priority of provisional application 60/332334, filed on Nov. 09, 2001.
Claims priority of provisional application 60/332493, filed on Nov. 09, 2001.
Claims priority of provisional application 60/277440, filed on Mar. 20, 2001.
Claims priority of provisional application 60/277431, filed on Mar. 20, 2001.
Claims priority of provisional application 60/277425, filed on Mar. 20, 2001.
Prior Publication US 2004/0219635 A1, Nov. 04, 2004
Int. Cl. C12Q 1/18 (2006.01); C12P 21/06 (2006.01); C12N 1/20 (2006.01); C12N 15/74 (2006.01); C07H 21/04 (2006.01)

U.S. Cl. 435—6  [435/69.1; 435/325; 435/252.3; 435/320.1; 536/23.5]

6 Claims

1. An isolated nucleic acid encoding a hypoxia inducible factor α (HIFα) mutein polypeptide, wherein said HIFα mutein polypeptide comprises the amino acid sequence set forth in SEQ ID NO: 2 except wherein: A) the amino acid residue at position 402 of said polypeptide sequence is not proline; B) the amino acid residue at position 562 of said polypeptide sequence is not leucine; and C) the amino acid residue at position 564 of said polypeptide sequence is any amino acid other than proline.